Moomoo AI 已提取核心訊息
On February 21, 2024, Novo Integrated Sciences, Inc. (Novo), along with its wholly-owned subsidiary Clinical Consultants International, LLC (CCI), announced a new Consulting Services Agreement with Futura Surgicare Pvt Ltd, a leading manufacturer of wound closure and surgical products known as Dolphin Sutures. The agreement aims to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products and to establish a strategic partnership for introducing Dolphin Sutures and mesh products to the North American healthcare market. This partnership is expected to bring cost savings and improved care to American patients and healthcare providers. Novo Integrated Sciences, headquartered in Bellevue, Washington, is focused on a multidisciplinary approach to patient-first health and wellness, integrating medical technology, advanced therapeutics, and rehabilitative science. The company operates on a decentralized healthcare model, emphasizing service networks, technology, and product development to enhance non-catastrophic healthcare delivery.
On February 21, 2024, Novo Integrated Sciences, Inc. (Novo), along with its wholly-owned subsidiary Clinical Consultants International, LLC (CCI), announced a new Consulting Services Agreement with Futura Surgicare Pvt Ltd, a leading manufacturer of wound closure and surgical products known as Dolphin Sutures. The agreement aims to assist Futura in obtaining U.S. FDA 510K approvals for its advanced surgical products and to establish a strategic partnership for introducing Dolphin Sutures and mesh products to the North American healthcare market. This partnership is expected to bring cost savings and improved care to American patients and healthcare providers. Novo Integrated Sciences, headquartered in Bellevue, Washington, is focused on a multidisciplinary approach to patient-first health and wellness, integrating medical technology, advanced therapeutics, and rehabilitative science. The company operates on a decentralized healthcare model, emphasizing service networks, technology, and product development to enhance non-catastrophic healthcare delivery.
2024年2月21日，Novo Integrated Sciences, Inc.（Novo）及其全資子公司臨床顧問國際有限責任公司（CCI）宣佈與Futura Surgicare Pvt Ltd簽訂新的諮詢服務協議，該公司是傷口閉合和手術產品的領先製造商，名爲Dolphin Sutures。該協議旨在協助Futura的先進外科產品獲得美國食品藥品管理局510K的批准，並建立戰略合作伙伴關係，將Dolphin Sutures和網狀產品引入北美醫療市場。預計這種夥伴關係將爲美國患者和醫療保健提供者節省成本並改善醫療服務。總部位於華盛頓州貝爾維尤的Novo Integrated Sciences專注於以多學科方法實現患者至上的健康和保健，整合了醫療技術、先進療法和康復科學。該公司以分散的醫療模式運營，強調服務網絡、技術和產品開發，以增強非災難性醫療保健的提供。
2024年2月21日，Novo Integrated Sciences, Inc.（Novo）及其全資子公司臨床顧問國際有限責任公司（CCI）宣佈與Futura Surgicare Pvt Ltd簽訂新的諮詢服務協議，該公司是傷口閉合和手術產品的領先製造商，名爲Dolphin Sutures。該協議旨在協助Futura的先進外科產品獲得美國食品藥品管理局510K的批准，並建立戰略合作伙伴關係，將Dolphin Sutures和網狀產品引入北美醫療市場。預計這種夥伴關係將爲美國患者和醫療保健提供者節省成本並改善醫療服務。總部位於華盛頓州貝爾維尤的Novo Integrated Sciences專注於以多學科方法實現患者至上的健康和保健，整合了醫療技術、先進療法和康復科學。該公司以分散的醫療模式運營，強調服務網絡、技術和產品開發，以增強非災難性醫療保健的提供。
有用
沒用